Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mifamurtide - Takeda America Holdings

Drug Profile

Mifamurtide - Takeda America Holdings

Alternative Names: CGP 19835; CGP 19835A; Junovan; L-MTP-PE; Liposomal MTP-PE; Mepact; MLV 19835A; MTP-PE; Muramyltripeptide phosphatidylethanolamine

Latest Information Update: 23 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Medison Pharma; Takeda America Holdings
  • Class Antineoplastics; Drug conjugates; Ethanolamines; Immunoconjugates; Peptides
  • Mechanism of Action Macrophage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteosarcoma
  • Discontinued HIV infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Apr 2017 Launched for Osteosarcoma (Non-metastatic) in Venezuela, South Korea, Ukraine, and Brazil (IV) before April 2017
  • 01 Oct 2014 Registered for Osteosarcoma in Brazil (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top